JP2019523302A - 腋臭を治療する方法 - Google Patents

腋臭を治療する方法 Download PDF

Info

Publication number
JP2019523302A
JP2019523302A JP2019526209A JP2019526209A JP2019523302A JP 2019523302 A JP2019523302 A JP 2019523302A JP 2019526209 A JP2019526209 A JP 2019526209A JP 2019526209 A JP2019526209 A JP 2019526209A JP 2019523302 A JP2019523302 A JP 2019523302A
Authority
JP
Japan
Prior art keywords
examples
seq
sequence
homologous
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019526209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523302A5 (enExample
Inventor
エル． カスパー、ロジャー
エル． カスパー、ロジャー
ブイ． バーカー、トーマス
ブイ． バーカー、トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019523302A publication Critical patent/JP2019523302A/ja
Publication of JP2019523302A5 publication Critical patent/JP2019523302A5/ja
Priority to JP2022127495A priority Critical patent/JP2022169627A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2019526209A 2016-07-29 2017-07-31 腋臭を治療する方法 Pending JP2019523302A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022127495A JP2022169627A (ja) 2016-07-29 2022-08-10 腋臭を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662368896P 2016-07-29 2016-07-29
US62/368,896 2016-07-29
PCT/US2017/044731 WO2018023126A1 (en) 2016-07-29 2017-07-31 Methods of treating osmidrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022127495A Division JP2022169627A (ja) 2016-07-29 2022-08-10 腋臭を治療する方法

Publications (2)

Publication Number Publication Date
JP2019523302A true JP2019523302A (ja) 2019-08-22
JP2019523302A5 JP2019523302A5 (enExample) 2020-09-17

Family

ID=61016798

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019526209A Pending JP2019523302A (ja) 2016-07-29 2017-07-31 腋臭を治療する方法
JP2022127495A Pending JP2022169627A (ja) 2016-07-29 2022-08-10 腋臭を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022127495A Pending JP2022169627A (ja) 2016-07-29 2022-08-10 腋臭を治療する方法

Country Status (5)

Country Link
US (3) US20210301289A1 (enExample)
EP (1) EP3491129A4 (enExample)
JP (2) JP2019523302A (enExample)
KR (1) KR20190123256A (enExample)
WO (1) WO2018023126A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019391791A1 (en) * 2018-12-03 2021-06-03 Eirion Therapeutics, Inc. Improved delivery of large agents
CN110124042A (zh) * 2019-05-28 2019-08-16 赵叶莲 不含铝的抑制腋臭的组合物
EP4019048A4 (en) * 2019-08-21 2023-10-04 The University of Tokyo ABCC11 INHIBITOR
WO2021257630A2 (en) * 2020-06-15 2021-12-23 Cutler Richelle Drugs and methods for reducing body odor and sweat
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103716A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
US20120150023A1 (en) * 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
US20120328702A1 (en) * 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions
US20160184279A1 (en) * 2014-12-10 2016-06-30 Transderm, Inc. METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2844805A1 (en) * 2011-08-16 2013-02-21 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103716A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
US20120150023A1 (en) * 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
US20120328702A1 (en) * 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions
US20160184279A1 (en) * 2014-12-10 2016-06-30 Transderm, Inc. METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER SCIENCE, 2010, VOL.101, NO.11, PP.2404-2410, JPN6021023899, ISSN: 0004766839 *
TOYODA,Y; ET AL: "REGULATION OF THE AXILLARY OSMIDROSIS-ASSOCIATED ABCC11 PROTEIN STABILITY BY N-LINKED 以下備考", PLOS ONE, vol. 11, JPN5019006856, 9 June 2016 (2016-06-09), pages 1 - 23, ISSN: 0004766838 *

Also Published As

Publication number Publication date
US20250188461A1 (en) 2025-06-12
KR20190123256A (ko) 2019-10-31
WO2018023126A1 (en) 2018-02-01
EP3491129A1 (en) 2019-06-05
US20210301289A1 (en) 2021-09-30
US20240167028A1 (en) 2024-05-23
JP2022169627A (ja) 2022-11-09
EP3491129A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
US20250188461A1 (en) Methods of treating osmidrosis
JP2021105015A (ja) ナノ粒子組成物、その製剤およびその使用
KR101848095B1 (ko) 경피 운반
KR20140003572A (ko) 나노입자 조성물
Rosa et al. Current non-viral siRNA delivery systems as a promising treatment of skin diseases
BR112020010580A2 (pt) tratamento bacteriofágico para acne e biofilmes
Zhang et al. Microneedle delivery platform integrated with codelivery nanoliposomes for effective and safe androgenetic alopecia treatment
JP5674923B2 (ja) アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法
Li et al. Fabrication of carboxymethyl cellulose/hyaluronic acid/polyvinylpyrrolidone composite pastes incorporation of minoxidil-loaded ferulic acid-derived lignin nanoparticles and valproic acid for treatment of androgenetic alopecia
JP7548976B2 (ja) 皮膚透過性核酸複合体を有効成分として含有するアトピー皮膚炎の予防又は治療用組成物
RU2202362C2 (ru) Композиция для местного применения, содержащая фактор роста эпидермиса человека
CN107638304A (zh) 一种高皮肤细胞渗透的α‑熊果苷组合物及其制备方法和应用
KR20240028110A (ko) 유도만능줄기세포 유래 엑소좀 및 콜라겐을 유효성분으로 포함하는 조성물 및 이의 용도
JP2021535925A (ja) プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ−１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用
US8609147B2 (en) Use of deuterium oxide for treatment of herpes virus-based diseases of the skin
US20250275931A1 (en) Topical patch composition for targeted sirna nanoplex delivery and gene therapies and method of making and use thereof
JP2021507722A (ja) 核を標的とするｄｎａ修復酵素および使用方法
KR20160016475A (ko) Tslp 발현을 억제하는 올리고뉴클레오타이드 및 이를 포함하는 미용 또는 약제학적 조성물
US20230391825A1 (en) Enhanced skin permeation of a novel peptide via structural modification, chemical enhancement, and microneedles
WO2012105467A1 (ja) オリゴ核酸組成物及び抗アレルギー剤
KR20250083499A (ko) 통증 및 다른 의학적 병태의 치료를 위한 황화 글리코사미노글리칸 및 이것에서 유래한 단편의 저장에 안정한 제형
HK40052629A (en) Composition for preventing or treating atopic dermatitis comprising skin penetrating nucleic acid complex as an active ingredient
HK40052629B (zh) 包含皮肤穿透核酸复合物作为有效成分的用於预防或治疗特应性皮炎的组合物
Panchawat Some Aspects of Drug Delivery Through Nail: A Review
CN101115835A (zh) 具有茎环和无CpG基序的侧翼序列的CpG-ODN(寡聚脱氧核苷酸)用于治疗皮肤病

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510